NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT06480864 2025-01-06
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
China Medical University, China
Phase NA Recruiting
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT02945852 2022-07-19
Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Zhejiang Cancer Hospital
Phase 2 Completed
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown
NCT03547804 2020-12-01
MK 01
The First Hospital of Jilin University
Phase 2 Completed
NCT04453930 2020-07-01
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04128800 2019-10-16
Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03651219 2018-08-29
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
Beijing Chest Hospital
Phase 3 Unknown
NCT03135977 2017-12-07
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown